Kristin Peck is the CEO of Zoetis Inc. (NYSE: ZTS), the world’s largest animal health company with $9.5 billion in annual revenue. Appointed CEO in January 2020, Peck was instrumental in Zoetis’s 2013 IPO spin-off from Pfizer and has since grown the company into a global leader in veterinary medicine with a market capitalization exceeding $55 billion. A Georgetown University and Columbia Business School MBA graduate, Peck previously worked at Boston Consulting Group and held positions in private equity before joining Pfizer. She also serves on the board of directors of BlackRock and was named to TIME100 Health in 2025.
Read on to discover Zoetis CEO email address, Kristin Peck net worth in 2026, salary and compensation, career history, education, family, and more.
Quick Facts
| Kristin Peck — Key Information | |
|---|---|
| Full Name | Kristin C. Peck |
| Age | 53 years old (born ~1972) |
| Position | Chief Executive Officer |
| Company | Zoetis Inc. (NYSE: ZTS) |
| Tenure | January 2020 – present |
| Education | B.A., Georgetown University; MBA, Columbia Business School |
| 2024 Total Compensation | $17.2 million |
| Estimated Net Worth | $14 million+ |
| Board Seats | BlackRock, Business Roundtable |
| Headquarters | Parsippany, New Jersey |
| Employees | ~12,100 worldwide |
Career Highlights
- Led Zoetis since January 2020 — grew annual revenue from ~$6.7 billion to $9.5 billion, a 42% increase
- Instrumental in Zoetis’s 2013 IPO — helped evaluate and execute the spin-off from Pfizer, creating a standalone animal health powerhouse
- Named to TIME100 Health (2025) — recognized for advancing global animal health and the One Health approach
- Board member of BlackRock — serves on the board of the world’s largest asset manager ($10+ trillion AUM)
- CNBC Changemaker (2024) and Barron’s Top CEO (2022)
- Author of “Perseverance” — a memoir about her personal journey to parenthood, with all proceeds donated to charity
Kristin Peck Net Worth & Salary
As of 2026, Kristin Peck’s net worth is estimated at approximately $14 million or more, based on her disclosed Zoetis stock holdings and SEC insider trading filings. She has been CEO since January 2020, during which time Zoetis has significantly grown in both revenue and market value.
CEO Compensation Breakdown (FY2024)
| Component | Amount (USD) | % of Total |
|---|---|---|
| Base Salary | $1,306,000 | 7.6% |
| Annual Cash Bonus | $2,000,000 | 11.6% |
| Stock Awards (PSUs + RSUs) | $11,700,000 | 68.0% |
| Other Compensation | $2,200,760 | 12.8% |
| Total Compensation | $17,206,760 | 100% |
Key Insight: Over 92% of Kristin Peck’s total compensation is performance-based (bonus + equity), with only 7.6% from base salary. Approximately 80% of her long-term equity awards are Performance Share Units (PSUs) tied to Relative Total Shareholder Return.
Zoetis Financial Summary
Zoetis is a highly profitable Fortune 500 company. Under Kristin Peck’s leadership, the company has delivered consistent revenue growth and expanding margins, driven by strong demand for companion animal and livestock products worldwide.
| Metric | FY2025 | FY2024 | YoY Change |
|---|---|---|---|
| Revenue | $9.5B | $9.3B | ▲ +2% |
| Organic Revenue Growth | +6% | +12% | ▼ -6pp |
| Net Income | $2.7B | $2.5B | ▲ +8% |
| Adjusted Net Income | $2.8B | $2.7B | ▲ +6% |
| Adjusted EPS | $6.41 | $5.92 | ▲ +8% |
| Market Capitalization | ~$56B | ~$80B | ▼ -30% |
| 2026 Revenue Guidance | $9.83B – $10.03B | ▲ 3–5% organic growth | |
Growth Driver: Companion animal products grew 7% in FY2025, while livestock products surged 9% on a reported basis. Zoetis’s blockbuster products include Simparica Trio (flea/tick), Apoquel (dermatology), and Librela (pain management).
Zoetis Competitors
Zoetis holds approximately 20-25% of the global animal health market, which is valued at over $34 billion. Key competitors include:
- Merck Animal Health (MSD) — $5.6B revenue; vaccines, pharmaceuticals, and biologics for animals
- Boehringer Ingelheim Animal Health — $5.2B revenue; second-largest global animal health company
- Elanco Animal Health — spun off from Eli Lilly; companion animal and livestock products
- IDEXX Laboratories — leader in veterinary diagnostics and software
- Dechra Pharmaceuticals — UK-based specialty veterinary pharma (acquired by EQT in 2024)
- Virbac — French animal health company focused on companion animals and livestock
- Ceva Animal Health — private French company, strong in poultry and ruminant health
Zoetis CEO Email Address | Kristin Peck Contact
Below are the official contact details for Zoetis Inc. and CEO Kristin Peck:
| Contact Information | |
|---|---|
| Corporate Email | [email protected] (corporate format) |
| Investor Relations | [email protected] |
| Corporate HQ | 10 Sylvan Way, Parsippany, NJ 07054 |
| Phone | (973) 822-7000 |
| Kristin Peck – CEO at Zoetis Inc. | |
| Website | zoetis.com |
Career & Education – Company, University, & College
Kristin Peck’s career spans consulting, private equity, and pharmaceutical leadership. She spent over 15 years at Pfizer before transitioning to lead Zoetis as CEO.
Kristin Peck Career Timeline
| Period | Role | Organization |
|---|---|---|
| Early Career | Bachelor of Arts | Georgetown University |
| 1999 | MBA | Columbia Business School |
| Late 1990s | Management Consultant | Boston Consulting Group |
| Early 2000s | Private Equity / Real Estate | Prudential Realty, The O’Connor Group, J.P. Morgan |
| ~2003–2012 | EVP, Worldwide Business Development & Innovation | Pfizer Inc. |
| 2012–2013 | Led strategic evaluation of Pfizer Animal Health | Pfizer / Zoetis |
| 2013 | Key role in Zoetis IPO (spin-off from Pfizer) | Zoetis Inc. |
| 2013–2019 | Various leadership roles: Global Manufacturing, Poultry, Diagnostics, Corp. Development | Zoetis Inc. |
| Jan 2020 – Present | Chief Executive Officer | Zoetis Inc. |
Education
| University | Degree / Program |
|---|---|
| Georgetown University | Bachelor of Arts |
| Columbia Business School | Master of Business Administration (MBA), Class of 1999 |
Kristin Peck Wiki – Age, Family, & More
Zoetis CEO Kristin Peck is approximately 53 years old (born circa 1972). She resides in the Connecticut area with her husband Bob and their two children, Taylor and Connor. Peck is an accomplished author — she wrote Perseverance, a memoir about her journey to parenthood that included multiple miscarriages, fertility treatments, surrogacy, and adoption. She donated 100% of the book’s proceeds to Family and Children’s Agency.
Outside of Zoetis, Peck serves on the board of BlackRock, the world’s largest asset manager. She is a member of the Business Roundtable and has been recognized with numerous honors including:
- TIME100 Health (2025) — recognized for advancing global animal health
- CNBC Changemakers (2024)
- Barron’s Top CEOs (2022)
Peck is a strong advocate for the “One Health” approach — the idea that human, animal, and environmental health are interconnected. Under her leadership, Zoetis has expanded its focus on antimicrobial resistance and sustainable livestock practices.
About Zoetis Inc.
Zoetis Inc. (NYSE: ZTS) is the world’s largest animal health company, dedicated to discovering, developing, manufacturing, and marketing vaccines, medicines, diagnostics, and technologies for companion animals and livestock. Spun off from Pfizer in 2013, Zoetis operates in more than 100 countries with approximately 12,100 employees worldwide.
Key products include:
- Simparica Trio — leading flea, tick, and heartworm prevention for dogs
- Apoquel — treatment for allergic itch in dogs
- Librela — first-of-its-kind monoclonal antibody for pain management in dogs and cats
- Cytopoint — injectable antibody for canine atopic dermatitis
- Poultry and livestock vaccines — protecting global food supply chains
Zoetis generated $9.5 billion in revenue in FY2025 and is a member of the Fortune 500 and the S&P 500. The company is headquartered in Parsippany, New Jersey.
Frequently Asked Questions (FAQ)
Who is the CEO of Zoetis?
Kristin Peck has been CEO of Zoetis since January 2020. She played a key role in the company’s 2013 IPO spin-off from Pfizer and has grown Zoetis into a $55+ billion market cap global leader in animal health.
What is Kristin Peck’s net worth in 2026?
As of 2026, Kristin Peck’s net worth is estimated at approximately $14 million or more, based on her disclosed Zoetis stock holdings and SEC insider trading filings.
What is the Zoetis CEO salary?
Kristin Peck’s total compensation for fiscal year 2024 was approximately $17.2 million, including a $1.3 million base salary and over $13.7 million in performance-based bonuses and stock awards. Over 92% of her pay is performance-linked.
What is Zoetis CEO’s email address?
Kristin Peck can be reached via Zoetis’s corporate email format at [email protected]. For investor inquiries, contact [email protected]. The corporate phone number is (973) 822-7000.
What does Zoetis do?
Zoetis is the world’s largest animal health company, developing and selling vaccines, medicines, diagnostics, and technologies for both companion animals (pets) and livestock. Key products include Simparica Trio, Apoquel, and Librela.
Was Zoetis part of Pfizer?
Yes. Zoetis was Pfizer’s animal health division until it was spun off in a 2013 IPO. Kristin Peck was instrumental in evaluating and executing the spin-off and later became CEO in January 2020.
Article last updated: January 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including SEC filings, official company press releases, and reputable news outlets. This content is provided for informational purposes only and does not constitute financial or investment advice. Net worth figures are estimates and may vary by source.